Targeted HTS Expansion BellBrook Labs strategic expansion into RNA helicase ATPase and unwinding activity assays creates new high-throughput screening (HTS) opportunities for pharma partners focusing on RNA biology and antiviral targets, suggesting potential upsell of Transcreener HTS platforms to support these novel assays.

Regional Partnerships Nordic and Baltic region collaboration with Nordic Biosite expands BellBrook’s geographic reach, presenting channels for co-marketing, regional sales alignment, and access to new biopharma customers seeking HTS services and assay kits.

HTS Ready Solutions Recent launches of HTS compatible assays including SIRT activity real-time detection and the Transcreener platform position BellBrook as a one-stop provider for assay development, validation, and screening workflows—a compelling cross-sell to labs needing turnkey screening solutions.

Strategic Collaborations Collaboration with SPT Labtech to integrate Transcreener ADP2 with Dragonfly discovery systems signals a joint value proposition for customers seeking optimized miniaturized HTS platforms, enabling joint sales pitches and bundled offerings.

Funding & Validation A history of SBIR funding and notable project milestones in autoimmune targets (cGAS inhibitors) demonstrates credible validation and potential for grant-backed co-development deals with pharma, providing talking points for risk-mitigated partnerships and co-funded opportunities.